相关实验视频

Updated: Jul 20, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

一种由DC瘤融合细胞制备的新型热冲击蛋白70基疫苗:一个更新

Desheng Weng¹, Stuart K Calderwood², Jianlin Gong¹

¹Department of Medicine, Boston University School of Medicine, Boston, MA, USA.

Methods in molecular biology (Clifton, N.J.)

|August 4, 2023

概括

研究人员使用化瘤和树突细胞创建了一种改进的分子护送疫苗. 这种Hsp70.PC-F疫苗显示出更高的免疫原性,用于增强癌症免疫疗法.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
生物技术是生物技术.

背景情况:

分子伴侣,如热冲击蛋白70 (Hsp70),在抗原呈现中发挥作用.
目前的癌症疫苗在有效地向免疫系统呈现瘤抗原方面经常面临挑战.

研究的目的:

用一种新型细胞融合技术开发一种增强的基于分子伴侣的疫苗.
通过利用树突细胞对瘤抗原的处理来提高癌症疫苗的免疫性.

主要方法:

通过将瘤细胞与树突细胞融合以分离HSP70.PC-F的培养Hsp70.PC-F,以分离HSP70复合体.
利用细胞融合将瘤抗原引入树突细胞的抗原处理机器.
评估了Hsp70.PC-F疫苗配方的免疫性.

主要成果:

与单独来自瘤细胞的疫苗相比,Hsp70.PC-F配方表现出更高的免疫性.
细胞融合有效地转移了瘤抗原,由树突细胞进行处理.
在融合后实现了Hsp70复合物的快速分离.

结论:

Hsp70.PC-F代表了一种改进的配方,用于伴侣蛋白质基础的瘤疫苗.
细胞融合方法增强了瘤抗原的呈现,导致更大的免疫性.
这种方法为开发更有效的癌症免疫疗法提供了一个有希望的策略.

关键词:

细胞融合是细胞的融合.树突细胞 (DC) 是指树突细胞.提取Hsp70复合物 (Hsp70.PC) 的方法热冲击蛋白70 (Hsp70) 是一种热冲击蛋白.这是瘤疫苗.

更多相关视频

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

相关概念视频

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...